goat polyclonal anti cxcl13 antibody  (R&D Systems)

Journal: Frontiers in Immunology

Article Title: CXCL13 as a simple and promising blood biomarker for differentiating Sézary syndrome from mycosis fungoides and other confounding chronic inflammatory skin diseases

doi: 10.3389/fimmu.2026.1804103

Figure Lengend Snippet: CXCL13 mRNA expression in PBMCs from patients with Sézary syndrome and other confounding skin diseases. (A) Box-and-whisker plots showing individual CXCL13 ΔCt values in PBMCs from patients with Sézary syndrome (SS), mycosis fungoides (MF), atopic dermatitis (AD), psoriasis (PS) and healthy donors (HD). ΔCt values were calculated using GAPDH as housekeeping gene. Statistical significance was assessed using the Kruskal–Wallis test followed by Dunn’s multiple comparisons test. ***p ≤ 0.001; *p ≤ 0.05. (B) Relative CXCL13 expression levels expressed as fold change (RQ) for each disease group relative to HD, calculated using the mean ΔCt value of HD as reference. RQmin and RQmax represent the minimum and maximum relative quantities obtained by adding or subtracting, respectively, the standard deviation of ΔCt values to ΔΔCt.

Article Snippet: Sections were then incubated overnight at 4 °C with a goat polyclonal anti-CXCL13 antibody (AF801; R&D Systems) at a concentration of 2.5 μg/mL in 2% bovine serum albumin (BSA).

Techniques: Expressing, Whisker Assay, Standard Deviation

Journal: Frontiers in Immunology

Article Title: CXCL13 as a simple and promising blood biomarker for differentiating Sézary syndrome from mycosis fungoides and other confounding chronic inflammatory skin diseases

doi: 10.3389/fimmu.2026.1804103

Figure Lengend Snippet: CXCL13 immunohistochemical expression in skin biopsies from Sézary syndrome, mycosis fungoides and inflammatory skin diseases. Representative immunohistochemical staining for CXCL13 in skin lesions from patients with Sézary syndrome [SS; (A) ] and mycosis fungoides [MF; (B) ], showing CXCL13 expression in endothelial cells and neoplastic lymphocytes infiltrating the dermis, frequently displaying a dot-like staining pattern. In atopic dermatitis [AD; (C) ], psoriasis [PS; (D) ], eczema [EC; (E) ] and healthy donor skin [HD; (F) ], CXCL13 immunoreactivity is mainly confined to endothelial cells and scattered non-neoplastic lymphocytes. Sections were counterstained with haematoxylin. Original magnification: ×10; inserts ×40.

Article Snippet: Sections were then incubated overnight at 4 °C with a goat polyclonal anti-CXCL13 antibody (AF801; R&D Systems) at a concentration of 2.5 μg/mL in 2% bovine serum albumin (BSA).

Techniques: Immunohistochemical staining, Expressing, Staining

Journal: Frontiers in Immunology

Article Title: CXCL13 as a simple and promising blood biomarker for differentiating Sézary syndrome from mycosis fungoides and other confounding chronic inflammatory skin diseases

doi: 10.3389/fimmu.2026.1804103

Figure Lengend Snippet: Plasma CXCL13 levels and diagnostic performance in Sézary syndrome. (A) Box-and-whisker plots showing individual plasma CXCL13 concentrations in patients with Sézary syndrome (SS), mycosis fungoides (MF), atopic dermatitis (AD), psoriasis (PS), eczema (EC) and healthy donors (HD). Statistical significance was assessed using the Kruskal–Wallis test followed by Dunn’s multiple comparisons test. (B) Plasma CXCL13 concentrations in MF patients stratified according to disease stage at sampling (stage IB/IIA vs . advanced stages IIB and III). Statistical significance was assessed using the Mann–Whitney U test. (C) Receiver operating characteristic (ROC) curve analysis evaluating the ability of plasma CXCL13 to discriminate SS patients from all non-SS individuals (MF, AD, PS, EC and HD). The red cross indicates the selected cut-off value (151.1 pg/mL) maximising sensitivity (87%) and specificity (88%). (D) Box-and-whisker plots showing individual plasma CXCL13 concentrations in SS (right) and non-SS (left) patients. The dotted line indicates the ROC-derived cut-off value. Statistical significance was assessed using the Mann–Whitney U test. ****p ≤ 0.0001; **p ≤ 0.01; *p ≤ 0.05.

Article Snippet: Sections were then incubated overnight at 4 °C with a goat polyclonal anti-CXCL13 antibody (AF801; R&D Systems) at a concentration of 2.5 μg/mL in 2% bovine serum albumin (BSA).

Techniques: Clinical Proteomics, Diagnostic Assay, Whisker Assay, Sampling, MANN-WHITNEY, Derivative Assay

Journal: Cell and tissue research

Article Title: CXCL13 is expressed in a subpopulation of neuroendocrine cells in the murine trachea and lung.

doi: 10.1007/s00441-021-03552-2

Figure Lengend Snippet: Fig. 4 CXCL13 is expressed in two-thirds of the murine tracheal neuroendocrine cells. a, b Immunohistochemistry of tracheal whole mounts and the corresponding quantification of their immunoreactive cells; maximum intensity projec- tions of z-stacks of confocal optical sections. a Immuno- histochemistry with antibodies against CXCL13 (a) (green) and PGP9.5 (a′) (red), labeling single neuroendocrine cells and nerve fibers. CXCL13+/ PGP9.5+ cells are indicated by arrowheads; CXCL13−/ PGP9.5+ cells are indicated by ( <). Data points in the scatter plot (a‴) represent mean values of counts in one trachea (n = 5 tracheas); mean and SEM are indicated. The pie chart shows the percentages of CXCL13+/ PGP9.5+ and CXCL13−/ PGP9.5+ cells (n = 2254 cells pooled from 5 tracheas). b Immunohistochemistry with antibodies against CXCL13 (b) (green) and CGRP (b′) (red), labeling single neu- roendocrine cells and nerve fibers. CXCL13+/CGRP+ cells are indicated by arrowheads; CXCL13−/CGRP+ cells are indicated by ( <); CXCL13+/ CGRP− cells are indicated by (*). Data points in the scatter plot (b‴) represent mean values of counts in one trachea (n = 5 tracheas); mean and SEM are indicated. The pie chart shows the percentages of phenotypes (n = 2650 cells pooled from 5 tracheas)

Article Snippet: Floating sections were rinsed in PBS, and unspecific protein binding sites were saturated with 10% normal porcine serum in 0.005 M PBS for 1 h. Sections were incubated overnight with goat polyclonal antibody against CXCL13 (1:400 AF470, R&D Systems) or rabbit polyclonal antibody against αCGRP (1:20,000; T-4032, Peninsula Laboratories) followed by incubation for 1 h with peroxidase-conjugated pig anti-rabbit Ig (1:100; P0217, Dako, Santa Clara, USA) to detect CGRP or with biotinylated secondary donkey anti-goat IgG (1:400; 705–065- 147, Dianova) to detect CXCL13.

Techniques: Immunohistochemistry, Labeling

Journal: Cell and tissue research

Article Title: CXCL13 is expressed in a subpopulation of neuroendocrine cells in the murine trachea and lung.

doi: 10.1007/s00441-021-03552-2

Figure Lengend Snippet: Fig. 6 CXCL13 is less expressed in murine broncho- pulmonary solitary and clustered neuroendocrine cells. Immunohistochemistry of lung cryosections with antibodies against CXCL13 (orange) and CGRP (green) and the relative frequencies of immunoreactive phenotypes. a Solitary neuroen- docrine cell co-labeled with antibodies against CXCL13 and CGRP. b Solitary neu- roendocrine cell only labeled with antibodies against CGRP. c A cluster of neuroendocrine cells (neuroepithelial body) consisting of more than 7 cells, 2 of them are co-labeled with antibodies against CXCL13 and CGRP. d Pie chart shows percentages of CXCL13+/ CGRP+ and CXCL13−/CGRP+- immunolabeled cells in solitary neuroendocrine cells (n = 73 cells pooled from 5 animals). e Pie chart shows the percent- age of CXCL13+/CGRP+ and CXCL13−/CGRP+- immunolabeled cells in neu- roepithelial bodies (n = 1475 cells pooled from 5 animals)

Article Snippet: Floating sections were rinsed in PBS, and unspecific protein binding sites were saturated with 10% normal porcine serum in 0.005 M PBS for 1 h. Sections were incubated overnight with goat polyclonal antibody against CXCL13 (1:400 AF470, R&D Systems) or rabbit polyclonal antibody against αCGRP (1:20,000; T-4032, Peninsula Laboratories) followed by incubation for 1 h with peroxidase-conjugated pig anti-rabbit Ig (1:100; P0217, Dako, Santa Clara, USA) to detect CGRP or with biotinylated secondary donkey anti-goat IgG (1:400; 705–065- 147, Dianova) to detect CXCL13.

Techniques: Immunohistochemistry, Labeling, Immunolabeling

Journal: Cell and tissue research

Article Title: CXCL13 is expressed in a subpopulation of neuroendocrine cells in the murine trachea and lung.

doi: 10.1007/s00441-021-03552-2

Figure Lengend Snippet: Fig. 4 CXCL13 is expressed in two-thirds of the murine tracheal neuroendocrine cells. a, b Immunohistochemistry of tracheal whole mounts and the corresponding quantification of their immunoreactive cells; maximum intensity projec- tions of z-stacks of confocal optical sections. a Immuno- histochemistry with antibodies against CXCL13 (a) (green) and PGP9.5 (a′) (red), labeling single neuroendocrine cells and nerve fibers. CXCL13+/ PGP9.5+ cells are indicated by arrowheads; CXCL13−/ PGP9.5+ cells are indicated by ( <). Data points in the scatter plot (a‴) represent mean values of counts in one trachea (n = 5 tracheas); mean and SEM are indicated. The pie chart shows the percentages of CXCL13+/ PGP9.5+ and CXCL13−/ PGP9.5+ cells (n = 2254 cells pooled from 5 tracheas). b Immunohistochemistry with antibodies against CXCL13 (b) (green) and CGRP (b′) (red), labeling single neu- roendocrine cells and nerve fibers. CXCL13+/CGRP+ cells are indicated by arrowheads; CXCL13−/CGRP+ cells are indicated by ( <); CXCL13+/ CGRP− cells are indicated by (*). Data points in the scatter plot (b‴) represent mean values of counts in one trachea (n = 5 tracheas); mean and SEM are indicated. The pie chart shows the percentages of phenotypes (n = 2650 cells pooled from 5 tracheas)

Article Snippet: To further validate the specificity of the biotinylated secondary antibodies used in combination with the CXCL13 primary antibody, 10-μm-thick tracheal sections were air-dried for 1 h and unspecific protein binding sites were saturated with 10% normal swine serum in PBS + S (0.005 M phosphate buffer, with 0.15 M NaCl, pH 7.4) for 1 h. Sections were then incubated overnight either with goat polyclonal antibody to CXCL13 (1:400 AF470, R&D Systems) and rabbit polyclonal antibody to αCGRP (1:20,000; T-4032, Peninsula Laboratories) or with rabbit polyclonal antibody to αCGRP only.

Techniques: Immunohistochemistry, Labeling

Journal: Cell and tissue research

Article Title: CXCL13 is expressed in a subpopulation of neuroendocrine cells in the murine trachea and lung.

doi: 10.1007/s00441-021-03552-2

Figure Lengend Snippet: Fig. 6 CXCL13 is less expressed in murine broncho- pulmonary solitary and clustered neuroendocrine cells. Immunohistochemistry of lung cryosections with antibodies against CXCL13 (orange) and CGRP (green) and the relative frequencies of immunoreactive phenotypes. a Solitary neuroen- docrine cell co-labeled with antibodies against CXCL13 and CGRP. b Solitary neu- roendocrine cell only labeled with antibodies against CGRP. c A cluster of neuroendocrine cells (neuroepithelial body) consisting of more than 7 cells, 2 of them are co-labeled with antibodies against CXCL13 and CGRP. d Pie chart shows percentages of CXCL13+/ CGRP+ and CXCL13−/CGRP+- immunolabeled cells in solitary neuroendocrine cells (n = 73 cells pooled from 5 animals). e Pie chart shows the percent- age of CXCL13+/CGRP+ and CXCL13−/CGRP+- immunolabeled cells in neu- roepithelial bodies (n = 1475 cells pooled from 5 animals)

Article Snippet: To further validate the specificity of the biotinylated secondary antibodies used in combination with the CXCL13 primary antibody, 10-μm-thick tracheal sections were air-dried for 1 h and unspecific protein binding sites were saturated with 10% normal swine serum in PBS + S (0.005 M phosphate buffer, with 0.15 M NaCl, pH 7.4) for 1 h. Sections were then incubated overnight either with goat polyclonal antibody to CXCL13 (1:400 AF470, R&D Systems) and rabbit polyclonal antibody to αCGRP (1:20,000; T-4032, Peninsula Laboratories) or with rabbit polyclonal antibody to αCGRP only.

Techniques: Immunohistochemistry, Labeling, Immunolabeling

Journal: Molecular Therapy Oncolytics

Article Title: CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells

doi: 10.1016/j.omto.2021.07.003

Figure Lengend Snippet: Restricted normal T cell expression of CXCR5 and upregulation of CXCL13 in non-small cell lung cancer (NSCLC) (A) The expression of CXCL13 in patients with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) using the online tool of GEPIA. (B) CXCL13 protein expressions in NSCLC tissues were confirmed by immunohistochemistry on two tissue microarray slides (NSC157 and LC20813b). The intensity of immunostaining was graded as follows: −, negative; +, weak; ++, moderate; or +++, strong. (C) Expression of CXCL13 by immunohistochemistry. The subpanels show negative expression of CXCL13 (−), weak (+), moderate (++), and strong (+++) expressions of CXCL13 in tumor tissues ( ×400). (D) ELISA quantification of the level of CXCL13 protein in plasma samples (healthy donors n = 34, NSCLC patient donors n = 95). Single dot represents individual plasma sample. Error bars represent mean ± SD. ∗∗∗p < 0.001. (E) FACS analysis of the expression of different chemokine receptors from resting and activated T cells. Single dot represents individual sample. Error bars represent mean ± SD for each T cell population (n = 12).

Article Snippet: Primary polyclonal goat anti-human CXCL13 (cat. no. AF801, 1:20; R&D Systems) antibodies were applied and incubated in a humidified box overnight at 4°C.

Techniques: Expressing, Immunohistochemistry, Microarray, Immunostaining, Enzyme-linked Immunosorbent Assay, Clinical Proteomics

Journal: Molecular Therapy Oncolytics

Article Title: CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells

doi: 10.1016/j.omto.2021.07.003

Figure Lengend Snippet: Evaluation of the antitumor efficacy and chemotaxis migration of EGFR-CXCR5-CAR-T cells in vitro (A) Analysis of the cytotoxicity of EGFR-CXCR5-CAR-T cells against PC9, A549, and K562 cells. Tumor cell killing was measured via an IncuCyte assay over 48 h. SYTOX Green and CellTrace Far Red double-positive tumor cells (yellow) were calculated. Error bars represent mean ± SD for each time point. (B) Real-time cell killing image. Target cells were red, and CAR-T cells were green. (C) Cytokine production by CAR-T cells co-cultured with PC9 tumor cells. CAR-T cells were co-cultured 10:1 with tumor cells in 96-well plates for 20 h. Levels of IFN-γ and IL-2 in supernatant were determined by ELISA. Error bars represent mean ± SD for each group. (D) Chemotaxis migration of CAR-Ts toward various concentrations of recombinant human CXCL13 at different time courses of 4 h, 8 h, and 16 h. Error bars represent mean ± SD for each group (n = 3). ∗p < 0.05 derived via unpaired t test. (E) CAR-T cell proliferation assay with indicated CAR-T cells cocultured with various concentrations of recombinant human CXCL13.

Article Snippet: Primary polyclonal goat anti-human CXCL13 (cat. no. AF801, 1:20; R&D Systems) antibodies were applied and incubated in a humidified box overnight at 4°C.

Techniques: Chemotaxis Assay, Migration, In Vitro, Cell Culture, Enzyme-linked Immunosorbent Assay, Recombinant, Derivative Assay, Proliferation Assay

Journal: Molecular Therapy Oncolytics

Article Title: CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells

doi: 10.1016/j.omto.2021.07.003

Figure Lengend Snippet: In vivo tracking of the migration of 89 Zr-oxine-labeled CAR-T to A549 and A549-CXCL13 tumors using micro-PET/CT scan (A) EGFR expression in the A549 cell line stably expressing the CXCL13 gene (A549-CXCL13) after lentiviral transduction and selection. (B) Increased secretion of CXCL13 generated by A549-CXCL13 cells. ∗∗∗p < 0.001. (C) The effects of 89 Zr-oxine labeling on T cell proliferation. (D) Whole-body PET imaging, quantitative PET analysis, and biodistribution of 89 Zr-labeled T cells in tumor-bearing mice. 89 Zr-labeled mock T cells, 89 Zr-EGFR-CAR-T cells, or 89 Zr-EGFR-CXCR5-CAR-T cells were tail-vein injected into NSG mice inoculated with A549 tumor cells at the left and A549-CXCL13 tumor cells at the right side. Isotopic distribution of 89 Zr was quantified and plotted in a coronal horizon map at different time points of 2, 24, 72, and 168 h post-injection. The red and green circles represent the A549 tumor region and A549-CXCL13 tumor region, respectively. (E) Accumulated isotope signaling in A549 tumor region (green circle) and A549-CXCL13 tumor region (red circle). The percentage injection dose rate ([%ID]/g value) was calculated. Error bars represent mean ± SD for each group (n = 3).

Article Snippet: Primary polyclonal goat anti-human CXCL13 (cat. no. AF801, 1:20; R&D Systems) antibodies were applied and incubated in a humidified box overnight at 4°C.

Techniques: In Vivo, Migration, Labeling, Micro-PET, Computed Tomography, Expressing, Stable Transfection, Transduction, Selection, Generated, Imaging, Injection

Journal: Molecular Therapy Oncolytics

Article Title: CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells

doi: 10.1016/j.omto.2021.07.003

Figure Lengend Snippet: Antitumor efficacy of CAR-T cells in vivo (A) Serial bioluminescence imaging of NSG mice injected subcutaneously with A549 luc cells on the left flank and A549 luc -CXCL13 cells on the right flank. 10 days after tumor engraftment, the mice were injected with 5 × 10 5 CAR + T cells as indicated. n = 5 mice per group. Error bars represent mean ± SD for each time point (n = 5). (B) The tumor volume of the left tumors (A549 luc ) and right tumors (A549 luc -CXCL13) over 28 days was measured. Error bars represent mean ± SD for each time point (n = 5). (C) The copy number of CAR gene in the left and right tumor tissues was analyzed. ∗∗p < 0.01.

Article Snippet: Primary polyclonal goat anti-human CXCL13 (cat. no. AF801, 1:20; R&D Systems) antibodies were applied and incubated in a humidified box overnight at 4°C.

Techniques: In Vivo, Imaging, Injection

Journal: Molecular Therapy Oncolytics

Article Title: CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells

doi: 10.1016/j.omto.2021.07.003

Figure Lengend Snippet: Addition of CXCR5 facilitates T cell migration The chemokine CXCL13 is highly expressed in various tumors including lung carcinoma, whereas the classical CAR-T does not effectively infiltrate into tumor regions due to the absence of CXCR5 receptor expression. Chemotactic movement is a taxis in response to a chemical concentration gradient. When CAR-T cells are modified with the CXCR5 receptor, the motorized CAR-T cells could infiltrate into the tumor site along the gradient of CXCL13 to further clear the tumor cells.

Article Snippet: Primary polyclonal goat anti-human CXCL13 (cat. no. AF801, 1:20; R&D Systems) antibodies were applied and incubated in a humidified box overnight at 4°C.

Techniques: Migration, Expressing, Concentration Assay, Modification